---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-008650"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:14:14.411078+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbCellera FY2024 revenue $28.8M (down 24%), net loss $0.55/share; plans Phase 1 for two programs in 2025

## Summary
- Revenue $28.8M vs $38.0M in 2023; net loss $162.9M ($0.55 loss per share) vs $146.4M loss in 2023.
- Cash, securities and non-dilutive govt funding total approx. $840M in available liquidity.
- Cumulative partner program starts up to 96 (87 in 2023); 16 molecules in clinic (13 in 2023).
- Plans to initiate Phase 1 trials for ABCL635 and ABCL575 and start clinical manufacturing facility in 2025.

## SEC filing metadata
- accession: 0001628280-25-008650
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000162828025008650/0001628280-25-008650-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000162828025008650/abcl-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-008650
- JSON: https://secwatch.observer/filing/0001628280-25-008650.json
- Plain text: https://secwatch.observer/filing/0001628280-25-008650.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.